Experienced independent investor group, since late 1990, focused on public biotech companies in Nordic markets. We let our performance speak for itself.
Disclaimer. Our content is intended for informational purpose only. Our conclusion may be wrong and may cause losses. Do your own research before making any investment.
Coegin Pharma: Phase I/II AK study on track. Danish Medical Agency approve application to start the study. Coegin Pharma follows plan, start in August 2021. https://t.co/UiHSP0Cd8K
SynAct Pharma: Patients treated with AP1189 recovered respiratory function on average 3.5 days quicker than did placebo treated patients, a 35% increase in recovery time.
https://t.co/FnAlKtS890
Chordate Medical:
Clinical evaluation of Chordates K.O.S treatment for rhinitis in public hospitals in Saudi Arabia now approved https://t.co/3nSM4rUJGL
@petejmasters Don't know, not member of the fb-group. Bullish engulfing yesterday, PAS today have a conservative target of 60 SEK, should the Covid vaccine reach market the upside is even higher. In the ball park range we estimated to. However, we believe >100 SEK if vaccine is approved.
ExpreS2ion: gap closure today if you are into TA. Bullish engulfing candle in the making? Start phase II, financing sorted and phase I/II data upcoming.
@Success_X1 Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021
Portfolio update: We look forward to follow our new position in Coegin Pharma. Two spinouts and start of phase I/II in August, study completed this year. In our opinion, the two spinouts are not priced in at all in current market cap (likely value when launched 100-200 MSEK).
Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021